TODOS MED LTD ORD - TOMDF STOCK NEWS

Todos Medical (OTCQB: TOMDF) announced that its subsidiary 3CL Pharma received an Institutional Review Board (IRB) waiver to conduct a market research study on its Tollovid® and Tollovid Daily™ dietary supplements. The study aims to gather consumer feedback for potential product development in treating COVID and Long COVID. Concurrently, a 50% discount on Tollovid Maximum Strength is offered until May 31, 2022. The company leverages anecdotal success stories to drive sales and further research, indicating high interest from both physicians and customers.

Todos Medical, Ltd. (OTCQB: TOMDF) announced that its President and CEO, Gerald Commissiong, will present at the Emerging Growth Conference on April 27, 2022, from 10:00 am to 10:45 am EST. The company specializes in medical diagnostics, focusing on early cancer detection and neurodegenerative disorders. Todos has developed proprietary technologies, including the Todos Biochemical Infrared Analyses (TBIA) and tests like TMB-1 and TMB-2, both CE marked in Europe. The acquisition of Provista Diagnostics enhances its capabilities in PCR COVID testing and breast cancer diagnostics.

Todos Medical has appointed Philippe Goix as Chief Commercial Officer for its subsidiary, Provista Diagnostics, enhancing its management team for future growth. Goix, with over 25 years of experience, previously led successful diagnostics firms, including Singulex, where he scaled revenues to over $60 million. Under his leadership, Todos aims to maximize COVID-19 testing capabilities, recently achieving a high of 6,000 tests daily. The company is also set to launch a breast cancer test, Videssa, broadening its market reach beyond COVID diagnostics.

Todos Medical (OTCQB: TOMDF) announced a case study from Dr. Lee Morgentaler involving a patient who reported recovery from Long COVID symptoms after using the 3CL protease inhibitor dietary supplement, Tollovid®. The company has launched a new website for physicians to express interest in participating in a clinical study on Long COVID. CEO Gerald Commissiong emphasized the urgent need for validated diagnostic tools and clinical trials for Long COVID, highlighting the societal impact of the condition. Tollovid is noted for its potential benefits based on preliminary findings.

Todos Medical, Ltd. (OTCQB: TOMDF) announced the Informed Sport Certification for its product, Tollovid®, which is a proprietary 3CL protease inhibitor dietary supplement. This certification assures athletes that the product is free from banned substances, enhancing its marketability among elite athletes seeking immune support. The CEO, Gerald Commissiong, highlighted the importance of this certification for athletes and the potential for targeting this demographic. Tollovid is currently available for purchase on platforms including Amazon and MyTollovid.com.

Todos Medical, Ltd. (OTCQB: TOMDF) announced that its subsidiary 3CL Pharma supports the Biden Administration's effort to combat Long COVID, affecting over 22 million Americans. The FDA granted a Certificate of Free Sale for its dietary supplement Tollovid®, effective for both acute and chronic dosing. A recent case study showed complete symptom resolution in a Long COVID patient following Tollovid treatment. Additionally, the development of Tollovir™, a therapeutic candidate for severe COVID-19, reported promising Phase 2a clinical trial results.

Todos Medical, Ltd. (OTCQB: TOMDF) announced that its subsidiary 3CL Pharma's protease inhibitors, Tollovir® and Tollovid™, demonstrated robust inhibitory activity against multiple strains of the SARS-CoV-2 virus, including Omicron variants BA.1 and BA.2. The inhibitors showed IC50 binding affinities of <5 for Tollovid and <1 for Tollovir. The company awaits further data from its ongoing Phase 2a clinical trial for Tollovir, which has shown to enhance current COVID-19 treatment standards. Additionally, Todos plans to develop Tollovid into an OTC drug for various COVID-19 claims.

Todos Medical (OTCQB: TOMDF) reported financial results for Q4 and the full year ended December 31, 2021. Total revenue for 2021 reached $12.28 million, a 136% increase from $5.21 million in 2020. The company recorded a net loss of $41 million for 2021. Key developments include the acquisition of NLC Pharma's assets and positive Phase 2 clinical trial results for Tollovir, showing significant reduction in hospitalization days. Todos plans to launch the Videssa breast cancer test in 2023 and aims for a national stock exchange listing in 2022.

Todos Medical, Ltd. (OTCQB: TOMDF) reported a strong financial performance for 2021, with total revenue increasing by 136% to $12.28 million. The company is focused on expanding its COVID-19 testing and diagnostics capabilities and has achieved significant milestones, including positive Phase 2 clinical trial results for its Tollovir treatment. Despite posting a net loss of $41 million for the year, the acquisition of key assets enhances its market position. The upcoming Videssa breast cancer test and LymPro Alzheimer’s test are set for market introduction in 2022, aiming to drive further growth.